Neuroprotection

No large randomized controlled trials exist for neuroprotective peptides. NA-1 and P021 both failed in human translation. The majority of Semax and Selank clinical evidence originates from Russian-language literature with limited international replication.

Implications: Without large-scale RCTs, efficacy claims rest entirely on animal models and small pilot studies. The geographic concentration of evidence in Russian literature creates accessibility and verification barriers for the broader scientific community, limiting independent validation.

Receptor desensitization risk from chronic peptide use is theoretically established but clinically unquantified. Carcinogenesis risk from anti-apoptotic properties remains uninvestigated. Immunogenicity risk levels per administration route are poorly defined.

Implications: Patients self-administering neuroprotective peptides chronically have no evidence basis for long-term safety. The absence of longitudinal data means serious adverse effects — including cancer promotion and immune dysfunction — could emerge years after exposure without any surveillance system to detect them.

No FDA-approved dosing exists for Semax, Selank, P21, or Dihexa. Individual variability by genetics, age, and weight is uncharacterized. Optimal timing of intervention relative to disease stage is unknown for most target conditions.

Implications: Without standardized dosing, all current usage represents uncontrolled experimentation. Practitioners and self-experimenters rely on extrapolation from animal pharmacokinetics, community anecdotes, or arbitrary protocols. Under-dosing risks inefficacy while over-dosing risks toxicity, with no clinical framework to differentiate.

Ketone body effects on neuroprotective gene expression remain uninvestigated. P21's exact mechanism of action is still unknown despite years of research. Dihexa's core mechanism study was retracted in 2025, invalidating the foundational rationale for its use.

Implications: When the mechanistic basis for a compound's use is either unknown or actively discredited, rational dose optimization, combination therapy design, and adverse effect prediction become impossible. The Dihexa retraction specifically means that current users are taking a compound whose purported mechanism may be entirely fictional.

Gender-specific differences are underexplored — GLP-1 neuroprotection has only been demonstrated in female AD mouse models. Pediatric versus adult neurodegeneration responses are unstudied. Ethnic and genetic diversity in study populations is minimal.

Implications: Findings from homogeneous animal or human populations may not generalize. If GLP-1 neuroprotection is sex-dependent, half the patient population may derive no benefit. Pediatric traumatic brain injury and early-onset neurodegeneration remain entirely unaddressed by current peptide research.

Polypharmacy unknowns persist for peptide combinations with psychiatric medications. Nutraceutical interdependencies (B vitamins + Omega-3 for TBI/stroke) have not been systematically mapped. Selank interaction with CNS-active medications remains theoretical.

Implications: Many neuroprotection candidates will be administered alongside existing psychiatric or neurological medications. Without interaction data, clinicians cannot assess safety of combination regimens. Potentially synergistic nutraceutical stacks remain unoptimized while potentially dangerous pharmaceutical interactions go undetected.

Actual human brain concentration of administered peptides is unknown for most compounds. Shuttle peptide delivery mechanisms lack human pharmacokinetic data. Intranasal route absorption and CNS distribution are under-researched in human subjects.

Implications: Without confirmed human CNS penetration data, the fundamental premise of neuroprotection — that these peptides reach the brain at therapeutic concentrations — is unverified. Positive effects observed in animal models with direct CNS injection may be irrelevant to peripheral administration routes used by humans.